chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 54.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hypoaesthesia, Hypoaesthesia oral, Paraesthesia, Paraesthesia oral
Clinical narrative: lips started tingling and went numb. Within 10 minutes or so, the tingle/numbness travelled to my entire face and inside my mouth and tongue.; numbness travelled to inside my mouth and tongue; numbness travelled to my entire face; Tingling travelled to my entire face; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER BIONTECH COVID 19 mRNA VACCINE; lot number: EP6955) via unspecified route of administration in the left arm for COVID-19 immunisation on 27Mar2021 at 09:00 (at the age of 54-years-old). Medical history included obesity, osteoarthritis, neuritis and meralgia. Concomitant medications included omeprazole 10 mg (MANUFACTURER UNKNOWN), glucosamine (MANUFACTURER UNKNOWN), pyridoxine hydrochloride, magnesium lactate (MAGNES), and fish; all for unknown indication and from unknown date, unknown if ongoing. The patient previously received KEFLEX and amoxicillin (MANUFACTURER UNKNOWN), nitrofuran class (MACROBID); all on unknown dates for unspecified indications and experienced drug allergy. The patient had no food allergies. The patient did not receive any other vaccine within four weeks, prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, patient was not tested for COVID-19. On 27Mar2021 at 09:30, about 25 minutes after the vaccination, the patients lips started tingling and went numb and within 10 minutes the tingle/numbness travelled to entire face and inside mouth and tongue. This side effect randomly happens to the patient 2-3x/year, but she wasn't overly concerned and just watched it. The patient had no idea what triggers it, and stated so it may not be vaccine-related. The patient received self-treatment; popped two BENADRYL after waiting 90 minutes, as a treatment for the events. "Tingle/numb" were gone "1-1:30ish" (around 15 minutes). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events numbness of lips, mouth, tongue, entire face and tingling of lips, mouth, tongue and entire face was recovered on unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dysgeusia, Injection site pain, Injection site swelling
Clinical narrative: swollen sore right arm; Metal taste; swollen sore right arm; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730), via an unspecified route of administration in the right arm on 28Mar2021 at 16:15 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had a history of allergy to black ants, cockroaches and had seasonal allergies. Concomitant medication included cetirizine hydrochloride (ZYRTEC) for unspecified indication. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 28Mar2021 at 16:45, the patient experienced swollen sore right arm, and had metal taste which was like, she had a coin in her mouth that would not go away. She tried drinking lots of fluids, eating and mouth wash, which was not beneficial. Other than that, the patient felt fine. These events started about 30 minutes to an hour after the vaccination. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events swollen sore right arm and metal taste was not resolved at the time of report. No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dysgeusia, Pain in extremity, Peripheral swelling
Clinical narrative: swollen sore right arm; Metal taste; swollen sore right arm; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730), via an unspecified route of administration in the right arm on 28Mar2021 at 16:15 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had a history of allergy to black ants, cockroaches and had seasonal allergies. Concomitant medication included cetirizine hydrochloride (ZYRTEC) for unspecified indication. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 28Mar2021 at 16:45, the patient experienced swollen sore right arm, and had metal taste which was like, she had a coin in her mouth that would not go away. She tried drinking lots of fluids, eating and mouth wash, which was not beneficial. Other than that, the patient felt fine. These events started about 30 minutes to an hour after the vaccination. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events swollen sore right arm and metal taste was not resolved at the time of report. No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain upper, Chest X-ray, Computerised tomogram, Electrocardiogram, Lipase normal
Clinical narrative: Woke up 2.5 days later with extreme pain in upper abdomen; Only issue was lipase levels > 600; This is a spontaneous report from a contactable consumer (patient). A 52-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (Lot Number: EN6199) via an unspecified route of administration administered in left arm on 13Mar2021 at 12:00 (at 52 years old) as single dose for COVID-19 immunization. There were no other vaccinations within 4 weeks prior to the first dose of BNT162B2. Medical history included psoriatic arthritis and allergy to sulfa, both from unspecified date. Concomitant medications included etanercept (ENBREL) from unspecified date for unspecified indication. The patient previously took erythromycin (EMYCIN) and tetracycline and experienced allergy. It was unknown if the patient had COVID prior to vaccination. The patient was not tested for COVID post vaccination. The patient woke up 2.5 days later with extreme pain in upper abdomen and went to the emergency room (ER). The patient received fluids and pain medications. On 16Mar2021, gallbladder, chest X-ray, and electrocardiogram (EKG) were fine (as reported). The only issue was lipase levels of >600. All events started on 16Mar2021 at 03:00. The events resulted in ER visit. Outcome of the events was recovered on unspecified date in Mar2021.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lipids abnormal, Ultrasound biliary tract
Clinical narrative: Woke up 2.5 days later with extreme pain in upper abdomen; Only issue was lipase levels > 600; This is a spontaneous report from a contactable consumer (patient). A 52-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (Lot Number: EN6199) via an unspecified route of administration administered in left arm on 13Mar2021 at 12:00 (at 52 years old) as single dose for COVID-19 immunization. There were no other vaccinations within 4 weeks prior to the first dose of BNT162B2. Medical history included psoriatic arthritis and allergy to sulfa, both from unspecified date. Concomitant medications included etanercept (ENBREL) from unspecified date for unspecified indication. The patient previously took erythromycin (EMYCIN) and tetracycline and experienced allergy. It was unknown if the patient had COVID prior to vaccination. The patient was not tested for COVID post vaccination. The patient woke up 2.5 days later with extreme pain in upper abdomen and went to the emergency room (ER). The patient received fluids and pain medications. On 16Mar2021, gallbladder, chest X-ray, and electrocardiogram (EKG) were fine (as reported). The only issue was lipase levels of >600. All events started on 16Mar2021 at 03:00. The events resulted in ER visit. Outcome of the events was recovered on unspecified date in Mar2021.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain upper, Chest X-ray, Electrocardiogram, Investigation, Lipase
Clinical narrative: Woke up 2.5 days later with extreme pain in upper abdomen; Only issue was lipase levels > 600; This is a spontaneous report from a contactable consumer (patient). A 52-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (Lot Number: EN6199) via an unspecified route of administration administered in left arm on 13Mar2021 at 12:00 (at 52 years old) as single dose for COVID-19 immunization. There were no other vaccinations within 4 weeks prior to the first dose of BNT162B2. Medical history included psoriatic arthritis and allergy to sulfa, both from unspecified date. Concomitant medications included etanercept (ENBREL) from unspecified date for unspecified indication. The patient previously took erythromycin (EMYCIN) and tetracycline and experienced allergy. It was unknown if the patient had COVID prior to vaccination. The patient was not tested for COVID post vaccination. The patient woke up 2.5 days later with extreme pain in upper abdomen and went to the emergency room (ER). The patient received fluids and pain medications. On 16Mar2021, gallbladder, chest X-ray, and electrocardiogram (EKG) were fine (as reported). The only issue was lipase levels of >600. All events started on 16Mar2021 at 03:00. The events resulted in ER visit. Outcome of the events was recovered on unspecified date in Mar2021.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lipase increased
Clinical narrative: Woke up 2.5 days later with extreme pain in upper abdomen; Only issue was lipase levels > 600; This is a spontaneous report from a contactable consumer (patient). A 52-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (Lot Number: EN6199) via an unspecified route of administration administered in left arm on 13Mar2021 at 12:00 (at 52 years old) as single dose for COVID-19 immunization. There were no other vaccinations within 4 weeks prior to the first dose of BNT162B2. Medical history included psoriatic arthritis and allergy to sulfa, both from unspecified date. Concomitant medications included etanercept (ENBREL) from unspecified date for unspecified indication. The patient previously took erythromycin (EMYCIN) and tetracycline and experienced allergy. It was unknown if the patient had COVID prior to vaccination. The patient was not tested for COVID post vaccination. The patient woke up 2.5 days later with extreme pain in upper abdomen and went to the emergency room (ER). The patient received fluids and pain medications. On 16Mar2021, gallbladder, chest X-ray, and electrocardiogram (EKG) were fine (as reported). The only issue was lipase levels of >600. All events started on 16Mar2021 at 03:00. The events resulted in ER visit. Outcome of the events was recovered on unspecified date in Mar2021.
Age: 63.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Headache, Hypoaesthesia oral, Lip swelling
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received a first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730), via an unspecified route of administration in left arm on 25Mar2021 at 15:00 (at the age of 63-years-old) as a single dose for COVID-19 immunization. Medical history included low thyroxine, mildly elevated cholesterol, sprain and tendinitis. The patient had an allergic reaction to bee sting, had an allergic response to tetanus shot 40 years ago and had minor seasonal dust allergy and had outgrew sporadic childhood chocolate and strawberry allergies. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN), SYNTHROID and vitamin D (MANUFACTURER UNKNOWN) for unknown indications from unknown date. The patient had received other vaccine PROLIA, within 4 weeks prior to the COVID-19 vaccine in the arm on 04Mar2021 for an unknown indication. The patient had not been diagnosed with COVID-19 prior to the vaccination. The patient had not been tested for COVID-19 since the vaccination. On 25Mar2021, at 16:30, the patient had experienced numbing of lips, approximately 80 min after shot. The patient had received benadryl, followed by zantac as treatment for the events which prevented escalation. The patient had called the doctor later. The clinical outcome of numb lips was recovered at the time of report. No follow-up attempts are needed; No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hypoaesthesia oral
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received a first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730), via an unspecified route of administration in left arm on 25Mar2021 at 15:00 (at the age of 63-years-old) as a single dose for COVID-19 immunization. Medical history included low thyroxine, mildly elevated cholesterol, sprain and tendinitis. The patient had an allergic reaction to bee sting, had an allergic response to tetanus shot 40 years ago and had minor seasonal dust allergy and had outgrew sporadic childhood chocolate and strawberry allergies. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN), SYNTHROID and vitamin D (MANUFACTURER UNKNOWN) for unknown indications from unknown date. The patient had received other vaccine PROLIA, within 4 weeks prior to the COVID-19 vaccine in the arm on 04Mar2021 for an unknown indication. The patient had not been diagnosed with COVID-19 prior to the vaccination. The patient had not been tested for COVID-19 since the vaccination. On 25Mar2021, at 16:30, the patient had experienced numbing of lips, approximately 80 min after shot. The patient had received benadryl, followed by zantac as treatment for the events which prevented escalation. The patient had called the doctor later. The clinical outcome of numb lips was recovered at the time of report. No follow-up attempts are needed; No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chills, Fatigue, Headache, Pain, Throat tightness
Clinical narrative: Congestion of throat; Fatigue; Muscle ache; Chills; Headache; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER7613), via an unspecified route of administration in the left arm on 18Mar2021 at 17:00 (at the age of 37-years-old), as a single dose for COVID-19 immunisation. The patients medical history included penicillin allergy. The patient's concomitant medication included ibuprofen (MANUFACTURER UNKNOWN) for an unknown indication from unknown date. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 29Mar2021 at 09:00, the patient experienced fatigue, muscle aches, congestion in throat, chills and headache. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fatigue, myalgia, congestion in throat, chills and headache were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chills, Fatigue, Headache, Myalgia, Oropharyngeal discomfort
Clinical narrative: Congestion of throat; Fatigue; Muscle ache; Chills; Headache; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER7613), via an unspecified route of administration in the left arm on 18Mar2021 at 17:00 (at the age of 37-years-old), as a single dose for COVID-19 immunisation. The patients medical history included penicillin allergy. The patient's concomitant medication included ibuprofen (MANUFACTURER UNKNOWN) for an unknown indication from unknown date. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 29Mar2021 at 09:00, the patient experienced fatigue, muscle aches, congestion in throat, chills and headache. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fatigue, myalgia, congestion in throat, chills and headache were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Swelling, Tenderness
Clinical narrative: Lump under left armpit the size of a golf ball; Tender lump under left armpit.; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number ER2613) via an unspecified route of administration in the left arm on 25Mar2021, at 15:00 (at the age 62-years-old), as a single dose for COVID-19 immunisation. Medical history included breast cancer and atrial fibrillation(A-Fib). Allergies to medications included avelox, celebrex, lortab/vicaden, oxycodone/percocet. Concomitant medications received within 2 weeks of vaccination included apixaban (ELIQUIS), propafenone (MANUFACTURER UNKNOWN), pantoprazole (MANUFACTURER UNKNOWN), and atorvastatin (MANUFACTURER UNKNOWN). The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number EN6203) via an unspecified route of administration in the left arm on 04Mar2021, at 15:30 as a single dose for COVID-19 immunisation. The patient did not get any other vaccine within 4 weeks of COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 29Mar2021, the patient underwent COVID-19 molecular test and the result was negative. On 27Mar2021 at 04:00, the patient experienced event of lump under left armpit the size of a golf ball and event of tender lump under left armpit. The events did not result in doctor or other healthcare professional office/clinic visit. Treatment received for the adverse events was reported as no. The clinical outcome of event lump under left armpit the size of a golf ball and event tender lump under left armpit was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lymphadenopathy, SARS-CoV-2 test, Tenderness
Clinical narrative: Lump under left armpit the size of a golf ball; Tender lump under left armpit.; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number ER2613) via an unspecified route of administration in the left arm on 25Mar2021, at 15:00 (at the age 62-years-old), as a single dose for COVID-19 immunisation. Medical history included breast cancer and atrial fibrillation(A-Fib). Allergies to medications included avelox, celebrex, lortab/vicaden, oxycodone/percocet. Concomitant medications received within 2 weeks of vaccination included apixaban (ELIQUIS), propafenone (MANUFACTURER UNKNOWN), pantoprazole (MANUFACTURER UNKNOWN), and atorvastatin (MANUFACTURER UNKNOWN). The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number EN6203) via an unspecified route of administration in the left arm on 04Mar2021, at 15:30 as a single dose for COVID-19 immunisation. The patient did not get any other vaccine within 4 weeks of COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 29Mar2021, the patient underwent COVID-19 molecular test and the result was negative. On 27Mar2021 at 04:00, the patient experienced event of lump under left armpit the size of a golf ball and event of tender lump under left armpit. The events did not result in doctor or other healthcare professional office/clinic visit. Treatment received for the adverse events was reported as no. The clinical outcome of event lump under left armpit the size of a golf ball and event tender lump under left armpit was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Erythema, Pruritus, Urticaria
Clinical narrative: At 10:30 that evening I had a couple of hives.; At 10:30 that evening I had  a red stomach,; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: unknown) via an unspecified route of administration in the left arm on 24Mar2021 at 15:45 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included allergies. The patient was allergic to penicillin. Concomitant medications included cetirizine hydrochloride (ZYRTEC) and diphenhydramine hydrochloride (BENADRYL) from an unknown date for an unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, the patient was not tested with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 24Mar2021 at 22:30, the patient experienced hives and red stomach. Therapeutic measures were taken as a result of hives and red stomach and included treatment with BENADRYL. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of hives and red stomach were recovered at the time of the report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Erythema, Urticaria
Clinical narrative: At 10:30 that evening I had a couple of hives.; At 10:30 that evening I had  a red stomach,; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: unknown) via an unspecified route of administration in the left arm on 24Mar2021 at 15:45 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included allergies. The patient was allergic to penicillin. Concomitant medications included cetirizine hydrochloride (ZYRTEC) and diphenhydramine hydrochloride (BENADRYL) from an unknown date for an unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, the patient was not tested with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 24Mar2021 at 22:30, the patient experienced hives and red stomach. Therapeutic measures were taken as a result of hives and red stomach and included treatment with BENADRYL. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of hives and red stomach were recovered at the time of the report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 34.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dysphagia, Hypoaesthesia oral, Paraesthesia oral, Pharyngeal hypoaesthesia, Throat irritation
Clinical narrative: Mouth and tongue started tingling; Mouth and tongue started tingling; Mouth and tongue numbness; Throat numbness; Mouth and tongue numbness; Throat also got very itchy; Slightly difficult to swallow; This is a spontaneous report from a contactable consumer, the patient. A 34-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204), via an unspecified route of administration in arm left on 29Mar2021 at 11:15 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy- allergic to medications with sulfur and fruit allergy (Mango was the only food she have ever had a reaction to). Concomitant medications included ZYRTEC, NASACORT, turmeric/curcumin, vitamin D3, vitamin B12, vitamin C and zinc. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient was not diagnosed with Covid-19 prior to vaccination. Since the vaccination, the patient was not tested for COVID-19. On 29Mar2021 at 11:30, within 30 minutes after the shot, the patients mouth and tongue started tingling and feeling numb at the same time. It felt like there was swelling but the patient did not see swelling when she had a look in the mirror at the back of her throat and she was unsure whether the numbness might made it feel swollen. The patient described that her mouth, tongue and throat felt like she had just received a numbing injection at the dentist or gargled with lidocaine. The patient also got very itchy throat and it was slightly difficult to swallow. The patient stated that she took 50 mg of Benadryl upon arriving home after the vaccination. The numbness and tingling lasted about 7 hours. The patient clarified that she did not see a doctor as her breathing was fine and the next morning, her throat was still itchy but numbness and tingling were gone. The patient had taken Benadryl as a therapeutic measure for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events tingling mouth and tongue, numb mouth, numbness in tongue and numbness throat were recovered on 30Mar2021. The clinical outcome of itchy throat and swallowing difficult was recovering at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Incomplete course of vaccination, Pruritus, Throat tightness, Urticaria
Clinical narrative: itchy body welts; welts; tight throat; This is a spontaneous report from a contactable healthcare professional, nurse. A 29-years-old-non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6207) via intramuscular route of administration in the left arm on 09Mar2021 at 14:45 (at the age of 29-years-old) as a single dose for Covid-19 immunisation. The patient medical history and Concomitant medication was not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 09Mar2021 at 18:45, within 4 hours of first dose, the patient experienced tight throat. On the next day, 10Mar2021, the patient experienced itchy body welts. It was reported that the patient cancelled her 2nd dose after experiencing these events. No therapeutic measures were received as a result of the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events tight throat, itchy body and welts were recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pruritus, Throat tightness, Urticaria
Clinical narrative: itchy body welts; welts; tight throat; This is a spontaneous report from a contactable healthcare professional, nurse. A 29-years-old-non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6207) via intramuscular route of administration in the left arm on 09Mar2021 at 14:45 (at the age of 29-years-old) as a single dose for Covid-19 immunisation. The patient medical history and Concomitant medication was not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 09Mar2021 at 18:45, within 4 hours of first dose, the patient experienced tight throat. On the next day, 10Mar2021, the patient experienced itchy body welts. It was reported that the patient cancelled her 2nd dose after experiencing these events. No therapeutic measures were received as a result of the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events tight throat, itchy body and welts were recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Injection site paraesthesia, Injection site pruritus, Pruritus, Tachycardia
Clinical narrative: joint pain; Knee pain; Pain in elbow; Shoulder pain; Hand pain; Tachycardia; Tingling sensation in back, under arms, shoulder blade.; This is a spontaneous report from a contactable consumer. A 63-year-old non-pregnant female patient received an unspecified dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8732), via an unspecified route of administration on the left arm on 27Mar2021 (at the age 0f 63-year-old) at 14:00, as a single dose for COVID-19 immunisation. Medical history of the patient included autonomic instability, asthma, type 2, ehler -danlos and also allergic to codeine, talwin, cipro, ceftin, penicillin, sulfa, latex, dairy, poison ivy and sumac. Concomitant medications included sertraline (MANUFACTURER UNKNOWN), tramadol (MANUFACTURER UNKNOWN), gabapentin (MANUFACTURER UNKNOWN), and co-codamol (MANUFACTURER UNKNOWN). The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination the patient was not diagnosed with COVID-19 was unknown. Since vaccination, the patient had not tested for COVID-19. On 27Mar2021 at 20:00, the patient experienced joint pain originally only at the shoulder on injection side, over 48 hours it got spread to knees, elbows, shoulders and hands/thumbs tachycardia within 24 hours. The patient also experienced slight itchiness and tingling/burning sensation on back, underarm, bicep, trap and shoulder blades. The patient had received tylenol (MANUFACTURER UNKNOWN), NSAID (MANUFACTURER UNKNOWN), BENADRYL, atenolol (MANUFACTURER UNKNOWN) as treatment for the adverse events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events joint, knee, elbow shoulders and hands pain with burning and itching sensation on back, underarms, bicep, trap and shoulder blades was recovering.  No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Pain in extremity, Paraesthesia, Tachycardia
Clinical narrative: joint pain; Knee pain; Pain in elbow; Shoulder pain; Hand pain; Tachycardia; Tingling sensation in back, under arms, shoulder blade.; This is a spontaneous report from a contactable consumer. A 63-year-old non-pregnant female patient received an unspecified dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8732), via an unspecified route of administration on the left arm on 27Mar2021 (at the age 0f 63-year-old) at 14:00, as a single dose for COVID-19 immunisation. Medical history of the patient included autonomic instability, asthma, type 2, ehler -danlos and also allergic to codeine, talwin, cipro, ceftin, penicillin, sulfa, latex, dairy, poison ivy and sumac. Concomitant medications included sertraline (MANUFACTURER UNKNOWN), tramadol (MANUFACTURER UNKNOWN), gabapentin (MANUFACTURER UNKNOWN), and co-codamol (MANUFACTURER UNKNOWN). The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination the patient was not diagnosed with COVID-19 was unknown. Since vaccination, the patient had not tested for COVID-19. On 27Mar2021 at 20:00, the patient experienced joint pain originally only at the shoulder on injection side, over 48 hours it got spread to knees, elbows, shoulders and hands/thumbs tachycardia within 24 hours. The patient also experienced slight itchiness and tingling/burning sensation on back, underarm, bicep, trap and shoulder blades. The patient had received tylenol (MANUFACTURER UNKNOWN), NSAID (MANUFACTURER UNKNOWN), BENADRYL, atenolol (MANUFACTURER UNKNOWN) as treatment for the adverse events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events joint, knee, elbow shoulders and hands pain with burning and itching sensation on back, underarms, bicep, trap and shoulder blades was recovering.  No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Anxiety, Feeling abnormal, Panic attack
Clinical narrative: chest heavyness; Panic attack; Bad headache; sensation of anxiety; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;Lot Number: ER8733) via an unspecified route of administration in the arm left on 25Mar2021 at 11:15 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included gastritis and COVID-19. The patient received unspecified concomitant medications within two weeks of vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021 at 19:00, the patient experienced chest heaviness, panic attack, bad headache and sensation of anxiety. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient's received treatment with tylenol for the headache and xanax for the anxiety. The clinical outcome of the events chest heaviness, panic attack, bad headache and sensation of anxiety were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Anxiety, Chest discomfort, Headache, Panic attack
Clinical narrative: chest heavyness; Panic attack; Bad headache; sensation of anxiety; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;Lot Number: ER8733) via an unspecified route of administration in the arm left on 25Mar2021 at 11:15 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included gastritis and COVID-19. The patient received unspecified concomitant medications within two weeks of vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021 at 19:00, the patient experienced chest heaviness, panic attack, bad headache and sensation of anxiety. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient's received treatment with tylenol for the headache and xanax for the anxiety. The clinical outcome of the events chest heaviness, panic attack, bad headache and sensation of anxiety were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Fatigue, Lymphadenopathy, Myalgia, Nausea
Clinical narrative: Rash on face that is still here 3 weeks later.; tiredness; Headache; nausea; swollen lymph nodes; muscle and joint pain; muscle and joint pain; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER- BIONTECH COVID-19 mRNA vaccine, lot number: EL9263) via an unspecified route of administration in left arm on 06Mar2021 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient didn't take any concomitant medications. The patient was allergic to sulfa drugs. Prior to vaccination, the patient had not tested positive for COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient didn't receive any other vaccines within 4 weeks prior to the COVID vaccine. On 06Mar2021 at 16:00, the patient experienced rash on face, tiredness, headache, nausea, swollen lymph nodes, muscle pain and joint pain. It was reported patient had rash on face that was still there 3 weeks later. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as the result of adverse event rash on face, which included treatment with cream. The clinical outcome of the event rash on face was not recovered, while of tiredness, headache, nausea, swollen lymph nodes, muscle pain and joint pain was recovered on unknown date at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Rash, Specialist consultation
Clinical narrative: Rash on face that is still here 3 weeks later.; tiredness; Headache; nausea; swollen lymph nodes; muscle and joint pain; muscle and joint pain; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER- BIONTECH COVID-19 mRNA vaccine, lot number: EL9263) via an unspecified route of administration in left arm on 06Mar2021 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient didn't take any concomitant medications. The patient was allergic to sulfa drugs. Prior to vaccination, the patient had not tested positive for COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient didn't receive any other vaccines within 4 weeks prior to the COVID vaccine. On 06Mar2021 at 16:00, the patient experienced rash on face, tiredness, headache, nausea, swollen lymph nodes, muscle pain and joint pain. It was reported patient had rash on face that was still there 3 weeks later. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as the result of adverse event rash on face, which included treatment with cream. The clinical outcome of the event rash on face was not recovered, while of tiredness, headache, nausea, swollen lymph nodes, muscle pain and joint pain was recovered on unknown date at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Fatigue, Headache, Lymphadenopathy, Myalgia
Clinical narrative: Rash on face that is still here 3 weeks later.; tiredness; Headache; nausea; swollen lymph nodes; muscle and joint pain; muscle and joint pain; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER- BIONTECH COVID-19 mRNA vaccine, lot number: EL9263) via an unspecified route of administration in left arm on 06Mar2021 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient didn't take any concomitant medications. The patient was allergic to sulfa drugs. Prior to vaccination, the patient had not tested positive for COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient didn't receive any other vaccines within 4 weeks prior to the COVID vaccine. On 06Mar2021 at 16:00, the patient experienced rash on face, tiredness, headache, nausea, swollen lymph nodes, muscle pain and joint pain. It was reported patient had rash on face that was still there 3 weeks later. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as the result of adverse event rash on face, which included treatment with cream. The clinical outcome of the event rash on face was not recovered, while of tiredness, headache, nausea, swollen lymph nodes, muscle pain and joint pain was recovered on unknown date at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Nausea, Rash
Clinical narrative: Rash on face that is still here 3 weeks later.; tiredness; Headache; nausea; swollen lymph nodes; muscle and joint pain; muscle and joint pain; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER- BIONTECH COVID-19 mRNA vaccine, lot number: EL9263) via an unspecified route of administration in left arm on 06Mar2021 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient didn't take any concomitant medications. The patient was allergic to sulfa drugs. Prior to vaccination, the patient had not tested positive for COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient didn't receive any other vaccines within 4 weeks prior to the COVID vaccine. On 06Mar2021 at 16:00, the patient experienced rash on face, tiredness, headache, nausea, swollen lymph nodes, muscle pain and joint pain. It was reported patient had rash on face that was still there 3 weeks later. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as the result of adverse event rash on face, which included treatment with cream. The clinical outcome of the event rash on face was not recovered, while of tiredness, headache, nausea, swollen lymph nodes, muscle pain and joint pain was recovered on unknown date at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pharyngeal hypoaesthesia
Clinical narrative: Loss of feeling in throat; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733), via an unspecified route of administration in the arm left on 30Mar2021 at 14:45 (at the age of 40-year-old), as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205), via an unspecified route of administration in the arm left on 09Mar2021 at 13:45(at the age of 40-year-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021 at 15:00, the patient experienced loss of feeling in throat. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the adverse event and included treatment with BENADRYL on an unknown date. The clinical outcome of the event loss of feeling in throat was not recovered at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hyperacusis, Tinnitus
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 38-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6203) via unspecified route of administration in the left arm on 30Mar2021 at 09:30 as a single dose for COVID-19 immunisation (at the age of 38-years-old). Medical history included meniere's disease. The patient reported no allergies to medications, food and other products. Concomitant medication was claritin (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 30Mar2021 at 10:00 (30 minutes after), the patient experienced the shot she developed a loud ringing in her ears and sounds became amplified. 24 post vaccination there had not been any improvement. The tinnitus was very loud and the amplified noises are uncomfortable. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, emergency room/department or urgent care. The patient had not received treatment for event. The clinical outcome of event tinnitus was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tinnitus
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 38-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6203) via unspecified route of administration in the left arm on 30Mar2021 at 09:30 as a single dose for COVID-19 immunisation (at the age of 38-years-old). Medical history included meniere's disease. The patient reported no allergies to medications, food and other products. Concomitant medication was claritin (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 30Mar2021 at 10:00 (30 minutes after), the patient experienced the shot she developed a loud ringing in her ears and sounds became amplified. 24 post vaccination there had not been any improvement. The tinnitus was very loud and the amplified noises are uncomfortable. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, emergency room/department or urgent care. The patient had not received treatment for event. The clinical outcome of event tinnitus was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.